Related Experiment Video
Updated: Jun 22, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 26, 2010
The Maternal Phenylketonuria International Study: 1984-2002
Richard Koch1, William Hanley, Harvey Levy
1Childrens Hospital of Los Angeles and the University of Southern California School of Medicine, Los Angeles, California 90027, USA. rkoch8@earthlink.net
Early dietary control of phenylalanine (Phe) in pregnant women with hyperphenylalaninemia (HPA) significantly reduces offspring morbidity. Achieving Phe levels between 120-360 micromol/L by 8-10 weeks gestation is crucial for optimal birth outcomes.
Area of Science:
- Obstetrics
- Maternal-fetal Medicine
- Metabolic Disorders
Background:
- Hyperphenylalaninemia (HPA) poses risks to fetal development.
- A phenylalanine (Phe)-restricted diet is a key intervention for managing HPA during pregnancy.
Purpose of the Study:
- To assess the efficacy of a Phe-restricted diet in preventing morbidity in offspring of mothers with HPA.
- To review obstetric, psychological, and nutritional aspects of pregnancies in the Maternal Phenylketonuria Study.
Main Methods:
- 382 women with HPA were enrolled, completing 572 pregnancies.
- Statistical analyses included chi2, Fisher exact test, ANOVA, t-tests, Wilcoxon, and logistic regression.
- Outcomes were stratified by HPA classification and timing of dietary control.
Main Results:
- Optimal birth outcomes were achieved when maternal Phe levels were 120-360 micromol/L by 8-10 weeks gestation and maintained.
- Similar outcomes were observed for mild HPA mothers and those achieving control preconceptually or by 8-10 weeks.
Conclusions:
- Pre-conception counseling and early prenatal care are essential for optimal fetal outcomes in women with HPA.
- Achieving pre- and periconceptional dietary control with a Phe-restricted diet significantly reduces offspring morbidity.
More Related Videos
05:44Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 1
Published on: May 17, 2024
03:19Modifying Levels of Maternal Dietary Folic Acid or Choline to Study the Impact of Deficiencies on Offspring Health Outcomes
Published on: June 28, 2024
Related Concept Videos
Teratogenicity
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase